Corporate GovernanceApr 28, 2026, 04:33 PM
PDSB Amends 10-K: Governance, Executive Comp Restated
AI Summary
PDS Biotechnology Corp (PDSB) filed an amended Annual Report on Form 10-K/A to restate specific sections of Part III, including "Directors, Executive Officers and Corporate Governance," "Executive Compensation," and related stockholder matters. The amendment incorporates CEO and CFO certifications and provides updated details on the company's board structure, executive team, and compensation for named executive officers. The company clarified that this amendment does not alter any previously reported financial results or reflect events occurring after the original filing date.
Key Highlights
- PDSB filed a 10-K/A to amend and restate Items 10-14 of Part III of its original 10-K.
- The amendment includes CEO and CFO Rule 13a-14(a) certifications.
- No changes were made to previously reported financial results or events after the original 10-K filing date.
- The Board of Directors consists of 6 members, with Stephen Glover serving as Chairman.
- All directors, except CEO Frank Bedu-Addo and Ilian Iliev, are deemed independent.
- Frank Bedu-Addo's total compensation for 2025 was $828,307.
- Kirk Shepard's total compensation for 2025 was $677,318.
- Six officers/directors had late Form 4 filings in 2025 due to administrative oversights.
Price Impact
More from PDSB